Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors

/PRNewswire/ -- Today, Laekna Therapeutics announced that the investigational new drug (IND) application of a combination therapy for the phase 1/2 clinical...

Related Keywords

Shen Lin ,Henan ,China ,Shanghai ,Peking ,Beijing ,Chris Lu ,Yue Yong ,Eli Lilly ,University Hospital ,National Reimbursement Drug List ,Department Of Gastrointestinal Oncology ,National Medical Products Administration ,Cancer Institute ,Novartis ,Laekna Therapeutics ,Drug Evaluation ,Principal Investigator ,Professor Shen Lin ,Vice President ,Peking University Hospital ,Laekna Therapeutic ,Chief Medical Officer ,Therapeutics Chairman ,Guiding Principles ,Clinical Research ,Antitumor Pharmaceuticals Based ,Clinical Value ,Biologics License Application ,Health Care Amp Hospitals ,Pharmaceuticals ,Medical Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,